156 related articles for article (PubMed ID: 16334435)
1. One-year follow-up study of patients with enterochromaffin-like cell carcinoids after treatment with octreotide long-acting release.
Fykse V; Sandvik AK; Waldum HL
Scand J Gastroenterol; 2005 Nov; 40(11):1269-74. PubMed ID: 16334435
[TBL] [Abstract][Full Text] [Related]
2. Treatment of ECL cell carcinoids with octreotide LAR.
Fykse V; Sandvik AK; Qvigstad G; Falkmer SE; Syversen U; Waldum HL
Scand J Gastroenterol; 2004 Jul; 39(7):621-8. PubMed ID: 15370681
[TBL] [Abstract][Full Text] [Related]
3. Five-year follow-up of patients treated for 1 year with octreotide long-acting release for enterochromaffin-like cell carcinoids.
Jianu CS; Fossmark R; Syversen U; Hauso Ø; Fykse V; Waldum HL
Scand J Gastroenterol; 2011 Apr; 46(4):456-63. PubMed ID: 21133821
[TBL] [Abstract][Full Text] [Related]
4. Long-acting somatostatin analogues are an effective treatment for type 1 gastric carcinoid tumours.
Grozinsky-Glasberg S; Kaltsas G; Gur C; Gal E; Thomas D; Fichman S; Alexandraki K; Barak D; Glaser B; Shimon I; Gross DJ
Eur J Endocrinol; 2008 Oct; 159(4):475-82. PubMed ID: 18662970
[TBL] [Abstract][Full Text] [Related]
5. Involvement of BCL-2 oncoprotein in the development of enterochromaffin-like cell gastric carcinoids.
Azzoni C; Doglioni C; Viale G; Delle Fave G; De Boni M; Caruana P; Ferraro G; Bordi C
Am J Surg Pathol; 1996 Apr; 20(4):433-41. PubMed ID: 8604810
[TBL] [Abstract][Full Text] [Related]
6. Treatment of type I gastric neuroendocrine tumors with somatostatin analogs.
Khuroo MS; Khuroo MS; Khuroo NS
J Gastroenterol Hepatol; 2010 Mar; 25(3):548-54. PubMed ID: 20074162
[TBL] [Abstract][Full Text] [Related]
7. Follow-up of patients with ECL cell-derived tumours.
Sagatun L; Fossmark R; Jianu CS; Qvigstad G; Nordrum IS; Mjønes P; Waldum HL
Scand J Gastroenterol; 2016 Nov; 51(11):1398-405. PubMed ID: 27309188
[TBL] [Abstract][Full Text] [Related]
8. Activation and hyperplasia of gastrin and enterochromaffin-like cells in the stomach.
Håkanson R; Böttcher G; Sundler F; Vallgren S
Digestion; 1986; 35 Suppl 1():23-41. PubMed ID: 3539678
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness of octreotide in controlling fasting hypergastrinemia and related enterochromaffin-like cell growth.
Ferraro G; Annibale B; Marignani M; Azzoni C; D'Adda T; D'Ambra G; Bordi C; delle Fave G
J Clin Endocrinol Metab; 1996 Feb; 81(2):677-83. PubMed ID: 8636288
[TBL] [Abstract][Full Text] [Related]
10. Treatment of gastroenteropancreatic neuroendocrine tumours with octreotide LAR.
Tomassetti P; Migliori M; Corinaldesi R; Gullo L
Aliment Pharmacol Ther; 2000 May; 14(5):557-60. PubMed ID: 10792118
[TBL] [Abstract][Full Text] [Related]
11. Octreotide inhibits the enterochromaffin-like cell but not peroxisome proliferator-induced hypergastrinemia.
Bakke I; Sandvik AK; Waldum HL
J Mol Endocrinol; 2000 Aug; 25(1):109-19. PubMed ID: 10915223
[TBL] [Abstract][Full Text] [Related]
12. Netazepide, a gastrin receptor antagonist, normalises tumour biomarkers and causes regression of type 1 gastric neuroendocrine tumours in a nonrandomised trial of patients with chronic atrophic gastritis.
Moore AR; Boyce M; Steele IA; Campbell F; Varro A; Pritchard DM
PLoS One; 2013; 8(10):e76462. PubMed ID: 24098507
[TBL] [Abstract][Full Text] [Related]
13. [Study on histogenesis of enterochromaffin-like carcinoid in autoimmune atrophic gastritis associated with pernicious anemia].
Macukanović-Golubović L; Katić V; Rancić G; Milenović M; Marjanović G; Golubović Z
Vojnosanit Pregl; 2007 Aug; 64(8):543-8. PubMed ID: 17874722
[TBL] [Abstract][Full Text] [Related]
14. Partial gastric corpectomy results in hypergastrinemia and development of gastric enterochromaffinlike-cell carcinoids in the rat.
Mattsson H; Havu N; Bräutigam J; Carlsson K; Lundell L; Carlsson E
Gastroenterology; 1991 Feb; 100(2):311-9. PubMed ID: 1985029
[TBL] [Abstract][Full Text] [Related]
15. Spontaneous ECLomas in cotton rats (Sigmodon hispidus): tumours occurring in hypoacidic/hypergastrinaemic animals with normal parietal cells.
Cui G; Qvigstad G; Falkmer S; Sandvik AK; Kawase S; Waldum HL
Carcinogenesis; 2000 Jan; 21(1):23-7. PubMed ID: 10607729
[TBL] [Abstract][Full Text] [Related]
16. Enterochromaffin-like cell carcinoids of gastric mucosa in rats after life-long inhibition of gastric secretion.
Havu N
Digestion; 1986; 35 Suppl 1():42-55. PubMed ID: 3792671
[TBL] [Abstract][Full Text] [Related]
17. A meal test improves the specificity of chromogranin A as a marker of neuroendocrine neoplasia.
Jianu CS; Fossmark R; Syversen U; Hauso Ø; Waldum HL
Tumour Biol; 2010 Oct; 31(5):373-80. PubMed ID: 20480408
[TBL] [Abstract][Full Text] [Related]
18. Intermittent treatment of recurrent type-1 gastric carcinoids with somatostatin analogues in patients with chronic autoimmune atrophic gastritis.
Massironi S; Zilli A; Fanetti I; Ciafardini C; Conte D; Peracchi M
Dig Liver Dis; 2015 Nov; 47(11):978-83. PubMed ID: 26321479
[TBL] [Abstract][Full Text] [Related]
19. Serum chromogranin A as a screening test for gastric enterochromaffin-like cell hyperplasia during acid-suppressive therapy.
Sanduleanu S; De Bruïne A; Stridsberg M; Jonkers D; Biemond I; Hameeteman W; Lundqvist G; Stockbrügger RW
Eur J Clin Invest; 2001 Sep; 31(9):802-11. PubMed ID: 11589723
[TBL] [Abstract][Full Text] [Related]
20. Plasma chromogranin A in patients with autoimmune chronic atrophic gastritis, enterochromaffin-like cell lesions and gastric carcinoids.
Peracchi M; Gebbia C; Basilisco G; Quatrini M; Tarantino C; Vescarelli C; Massironi S; Conte D
Eur J Endocrinol; 2005 Mar; 152(3):443-8. PubMed ID: 15757862
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
